Cardiac RadiothErapy for VEntricular Tachycardia II

Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Dec 16, 2024

Keywords

ClinConnect Summary

The Cardiac RadiothErapy for VEntricular Tachycardia II trial is studying a treatment called Stereotactic Ablation for patients who have a heart condition known as Ventricular Tachycardia (VT). This condition involves the heart beating very fast and can be life-threatening. The trial aims to find out how effective and safe this treatment is in the long term for patients who have not responded to other therapies.

To participate, patients need to be between the ages of 65 and 74 and should have been deemed suitable for this treatment by a team of doctors. They must be able to provide written consent and agree to come back for follow-up visits. However, individuals who are pregnant, have had previous heart radiation therapy, or have a life expectancy of less than six months due to other health issues may not be eligible. Participants in this trial can expect close monitoring and support throughout the study to ensure their safety and well-being.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Eligible for STAR for therapy-refractory VT based on a multidisciplinary discussion
• • Ability to give a written informed consent and willingness to return for follow-up
• Exclusion Criteria:
• • Contra-indications for STAR, including pregnancy or breastfeeding, previous radiotherapy with cardiac involvement, life-expectancy \< 6 months in the absence of VT
• • Any condition that is deemed a contraindication in the judgment of the investigators